KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Dec 2024 value amounting to $2.21.

  • Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) fell 129.09% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.67, marking a year-over-year increase of 60.84%. This contributed to the annual value of $2.21 for FY2024, which is 154.02% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) stood at $2.21, which was up 154.02% from $0.87 recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year EPS (Weighted Average and Diluted) high stood at $4.50 for FY2020, and its period low was -$0.35 during FY2021.
  • In the last 3 years, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) had a median value of $0.87 in 2023 and averaged $1.28.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) spiked by 3,561.54% in 2020, and later tumbled by 107.78% in 2021.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's EPS (Weighted Average and Diluted) stood at $4.50 in 2020, then slumped by 107.78% to -$0.35 in 2021, then skyrocketed by 314.29% to $0.75 in 2022, then rose by 16.00% to $0.87 in 2023, then spiked by 154.02% to $2.21 in 2024.